Rosenblatt Tatiana R, Chiou Carolina A, Yoon Michael K, Lee Nahyoung Grace, Wolkow Natalie, Freitag Suzanne K
Department of Ophthalmology, Massachusetts Eye and Ear, Boston, Massachusetts, USA
Department of Ophthalmology, Massachusetts Eye and Ear, Boston, Massachusetts, USA.
Br J Ophthalmol. 2025 Apr 22;109(5):628-630. doi: 10.1136/bjo-2024-325527.
Prior studies of teprotumumab for thyroid eye disease report proptosis reduction in millimetres, which does not fully capture teprotumumab's clinical effect since a given number of millimetres change can be of variable impact depending on patients' degree of pre-treatment proptosis. In this retrospective study analysing proptosis change as a percentage of pre-treatment proptosis among 119 patients, 208 (87.4%) eyes of 110 patients had proptosis reduction averaging 14.4% (range 2.2-40.5%) of their pre-treatment proptosis, or 3.3 mm (range 0.5-10.0 mm). Reporting proptosis reduction as a percentage of pre-treatment proptosis provides a better understanding of teprotumumab's clinical impact.
